Leukemia

Management of cancer therapies in the era of COVID-19 infection and vaccination requires careful consideration of both disease and patient characteristics, according to members of a crossfire panel at Chemotherapy Foundation Symposium.

Significant progress has been made in treatment and improving survival outcomes across all subtypes of acute lymphoblastic leukemia, according to a speaker at Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.

The FDA granted orphan drug designation to SEL24/MEN1703 for the treatment of acute myeloid leukemia.

Incorporation of next-generation sequencing into standard of practice will be required for patients with myelodysplastic syndrome and will impact all facets of care, according to a presenter at Chemotherapy Foundation Symposium.

Three individuals have been elected to American Society of Hematology’s executive committee.

The FDA approved asciminib for treatment of certain patients with chronic myeloid leukemia, according to a press release from the agent’s manufacturer.

Expanded use of chimeric antigen receptor T cells for cancer treatment requires that less expensive therapies be developed faster using multiple manufacturing models, according to an FDA official.

The FDA cleared an investigational new drug application for PRGN-3007, a chimeric antigen receptor T-cell therapy for patients with advanced hematologic malignancies or solid tumors that express receptor tyrosine kinase-like orphan receptor 1.

The sense of urgency surrounding the COVID-19 pandemic led to speedy development of several vaccines against the SARS-CoV-2 virus.